

Date: January 7, 2025

To

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Creation of Pledge on the shares of Bharat Serums and Vaccines Limited

In continuation to our letter dated November 15, 2024 and pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that as per the terms and conditions of 3 Debenture Trust Deeds executed on October 10, 2024 between the Catalyst Trusteeship Limited and the Company for the issuance of listed, rated, secured, redeemable, transferable non-convertible debentures aggregating to INR 5,000 crores (“NCDs”) by the Company in 3 Series, remaining 56.31% equity shares of Bharat Serums and Vaccines Limited, wholly owned subsidiary of the Company (“BSV”) have also been pledged in favour of Catalyst Trusteeship Limited as the Common Security Trustee for the benefit of the holders of the NCDs.

The detailed disclosure as required SEBI Listing Regulations for aforesaid is enclosed as Annexure I.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Ashish Mittal
Company Secretary and Compliance Officer

Annexure – I

Disclosure as per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Details of event that needs to be provided	Details
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Not Applicable. Bharat Serums and Vaccines Limited (“BSV”) become the wholly Owned subsidiary of the Company on October 23, 2024.
2	Date on which the agreement for sale has been entered into;	As per the terms and conditions of Pledge Agreement executed on November 14, 2024 between the Catalyst Trusteeship Limited (“Common Security Trustee”), BSV and the Company, remaining 56.31% equity shares of BSV have also been pledged in favour of the Common Security Trustee as security for listed, rated, secured, redeemable, transferable non-convertible debentures aggregating to INR 5,000 crores (“NCDs”) issued by the Company in 3 Series pursuant to 3 debenture trust deeds.
3	The expected date of completion of sale/disposal	The equity shares will remain pledged until the settlement of NCDs
4	Consideration received from such sale/disposal;	Not Applicable
5	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	The transaction will not fall within related party transactions
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	

MANKIND PHARMA LIMITED